Category: Press Release - Page 66 - Psychedelic Alpha

Read more about the article Entheon Biomedical Announces Non-Brokered Private Placement Financing

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Post published:April 5, 2022
Post category:Press Release

Read more about the article Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

Post published:April 5, 2022
Post category:Press Release

Read more about the article MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Post published:April 5, 2022
Post category:Press Release

Read more about the article Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Post published:April 5, 2022
Post category:Press Release

Read more about the article Health Canada Approves First Special Access Program Requests for Psilocybin

Health Canada Approves First Special Access Program Requests for Psilocybin

Post published:April 4, 2022
Post category:Press Release

Read more about the article Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Post published:April 1, 2022
Post category:Press Release

Read more about the article Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

Post published:March 31, 2022
Post category:Press Release

Read more about the article Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Post published:March 31, 2022
Post category:Press Release

Read more about the article Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Post published:March 31, 2022
Post category:Press Release

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Post published:March 30, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.